Physician profile
Thomas J Carpenter
NPI 1952301699
$692.00
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $231 · 2021: $195 · 2022: $265.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $167.66 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.13 | 2022 | |
| Gilead Sciences, INC. | $91.96 | 2021 | |
| Eisai INC. | $72.97 | 2020 | |
| Allergan, INC. | $67.39 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $54.25 | 2021-2022 | |
| Amarin Pharma, INC. | $31.99 | 2020 | |
| Abbvie INC. | $26.71 | 2021 | |
| Novo Nordisk INC | $21.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.